Core Viewpoint - Derun Electronics has been penalized for financial fraud, leading to a significant fine and a change in stock status to "ST Derun" due to serious violations of information disclosure regulations [2][5][12]. Group 1: Financial Fraud Details - The financial fraud orchestrated by the actual controller, Qiu Jianmin, involved fabricating over 500 million yuan in receivables, resulting in a total fine of 22.5 million yuan [5][12]. - From 2020 to 2021, due to cash flow issues caused by major clients' operational difficulties, Qiu Jianmin implemented unconventional methods to create fictitious receivables of 395 million yuan and 113 million yuan, respectively [9][10]. - In 2022, the fraudulent activities became more complex, with the company fabricating receivables of 26.83 million yuan in its semi-annual report [10]. Group 2: Regulatory Actions and Penalties - The Shenzhen Securities Regulatory Commission issued a warning and imposed a fine of 7 million yuan on Derun Electronics, while Qiu Jianmin received a total fine of 12 million yuan and a five-year market ban [12][13]. - The company will face a one-day trading suspension on January 5, 2026, and will resume trading on January 6, 2026, under the new stock name "ST Derun" with a trading limit of 5% [5][14]. Group 3: Company Performance and Challenges - Derun Electronics reported a net loss of 1.225 billion yuan in 2024, marking a decline of over 500% year-on-year, primarily due to losing control over a significant subsidiary, Meta [15][18]. - In the first three quarters of 2025, the company experienced a revenue decline of 15.7% to 3.267 billion yuan, but net profit improved by 157.68% to 72.53 million yuan [18]. - The company's controlling shareholder, Shenzhen Desheng Asset Management Co., has seen its shareholding drop to 5.68% due to ongoing judicial auctions, raising concerns about potential changes in control [18]. Group 4: Market Position and Future Outlook - As of December 31, 2025, Derun Electronics' stock closed at 6.74 yuan per share, with a total market capitalization of 4.074 billion yuan [19]. - The company has indicated that it will apply to lift the risk warning after 12 months following the administrative penalty decision, emphasizing that the situation does not trigger mandatory delisting [14].

【导读】 得润电子1月6日起复牌并"戴帽" 中国基金报记者 夏天 2025年最后一个工作日，得润电子（证券代码： 002055 ）收到一则来自监管的重磅罚单。 公告显示，因连续多年财务造假， 得润电子 及相关责任人于2025年12月31日收到 深圳证监局 出具的 《行政处罚事先告知书》 。 这场由实际控制人之一邱建民主导、累计虚构超5亿元回款的财务操作，让公司及相关责任人面临合计2250万元的罚款， 邱建民 更被采取 5年证券市场禁入措施。 根据深交所相关规定，公司股票将于2026年1月5日停牌一天，自1月6日起复牌，并被实施其他风险警示，股票简称变更为"ST得润"，股 票交易日涨跌幅限制变为5%。 虚构回款致多期财务造假 到了2022年，造假手段进一步复杂化。2022年6月，邱建民指使 得润电子 子公司，以"预付货款"的名义向公司的联营企业提供资金。这 笔资金的真实用途，是用于该联营企业到期归还得润电子此前提供的财务资助款。这一操作导致公司 《 2022年半年度报告 》 虚构回款 2683.69万元，少计信用减值损失506.1万元。 上述行为直接导致得润电子《2020年年度报告》《2021年年度报告》及《2 ...

《告知书》称，得润电子涉嫌信息披露违法违规一案，已由深圳证监局调查完毕，深圳证监局依法拟对 公司作出行政处罚。经查： 公司股票简称将由"得润电子"变更为"ST得润"。 得润电子（002055）2025年12月31日晚间公告，2025年12月31日，公司及相关当事人收到中国证券监督 管理委员会深圳监管局（简称"深圳证监局"）出具的《行政处罚事先告知书》（简称《告知书》）。 结合公司已进行会计差错更正、积极配合调查以及相关款项已捐赠给公司等情节，根据当事人违法行为 的事实、性质、情节与社会危害程度，深圳证监局拟决定： 一、对深圳市得润电子股份有限公司给予警告，并处以700万元罚款； 二、对邱建民给予警告，并处以1200万元罚款（其中作为直接负责的主管人员处以400万元罚款，作为 实际控制人处以800万元罚款），另对邱建民采取5年证券市场禁入措施； 三、对邱扬给予警告，并处以200万元罚款； 四、对饶琦给予警告，并处以150万元罚款。 公告称，根据《深圳证券交易所股票上市规则（2025年修订）》第9.8.1条规定："上市公司出现下列情 形之一的，本所对其股票交易实施其他风险警示：（八）根据中国证监会行政处罚事先告知 ...

得润电子（002055）2025年12月31日晚间公告，2025年12月31日，公司及相关当事人收到 中国证券监督管理委员会深圳监管局（简称"深圳证监局"）出具的《行政处罚事先告知书》 （简称《告知书》）。 公司股票简称将由"得润电子"变更为"ST得润"。 《告知书》称，得润电子涉嫌信息披露违法违规一案，已由深圳证监局调查完毕，深圳证监 局依法拟对公司作出行政处罚。经查： 一、2020年至2021年，因得润电子主要客户等经营困难，无法偿还欠款，致使公司现金流紧 张，得润电子实际控制人、时任董事长、总裁邱建民通过自有资金、对外借款等方式，向得 润电子客户、原子公司、设备供应商等提供资金支持，用于前述主体向得润电子归还历史欠 款。邱建民未向得润电子报告上述资金实际来源，导致得润电子2020年、2021年分别虚构回 款3.95亿元、1.13亿元，少计信用减值损失3.71亿元、6639.31万元；少计资本公积3.21亿 元、4.34亿元。 二、2022年6月，邱建民指使得润电子子公司以预付货款的形式，间接向得润电子联营公司 提供资金，用于到期归还得润电子的财务资助款，导致得润电子2022年上半年虚构回款 2683.6 ...

公告显示，公司股票将自2026年1月5日(星期一)开市起停牌1天，自2026年1月6日(星期二)开市起复牌。 智通财经APP讯，得润电子(002055.SZ)公告，公司及相关当事人收到中国证券监督管理委员会深圳监管 局出具的《行政处罚事先告知书》。根据《行政处罚事先告知书》认定的情况，公司披露的《2020年年 度报告》《2021年年度报告》《2022年半年度报告》存在虚假记载，公司股票将被实施其他风险警示， 股票简称由"得润电子"变更为"ST得润";股票交易日涨跌幅限制为5%。 ...

Group 1 - The Nanjing Intermediate People's Court ruled on December 31, 2025, that over 43,000 investors in Jintongling (300091) will receive compensation exceeding 770 million yuan due to securities fraud [1][2] - This ruling is a preliminary judgment focusing on the company's liability, with further judgments pending regarding the responsibilities of the company's former executives and related intermediaries [1][2] - The case highlights the increasing application of representative litigation in China, moving from pilot exploration to a more standardized approach [1][2] Group 2 - The new "National Nine Articles" emphasizes the establishment of a comprehensive system to combat financial fraud and strengthen accountability in the capital market [2] - The China Securities Regulatory Commission (CSRC) has adopted a "zero tolerance" policy towards financial fraud, increasing regulatory enforcement and civil accountability mechanisms [2] - Jintongling has been involved in financial fraud for six consecutive years, inflating revenue by over 1.3 billion yuan and profits by 500 million yuan, and is currently undergoing bankruptcy restructuring [2] Group 3 - The special representative litigation system is seen as a significant tool for increasing the costs of illegal activities in the capital market and protecting the rights of small and medium investors [3] - Investor protection agencies play a crucial role in the representative litigation process, leveraging their public interest functions and professional advantages [4] - The China Securities Investor Services Center has been actively involved in representative litigation, ensuring fair compensation for affected investors [5] Group 4 - The Supreme Court and the CSRC have issued guidelines to support investor protection agencies in fulfilling their roles in representative litigation [6] - There is a growing emphasis on the effectiveness of ordinary representative litigation in resolving collective securities disputes and protecting investor rights [6] - The China Securities Investor Services Center has increased its involvement in ordinary representative litigation, enhancing the collaborative effect of both types of litigation [6] Group 5 - The Supreme Court's 2020 judicial interpretation of representative litigation has played a significant role in enforcing securities laws and facilitating investor rights protection [7] - There is a need to refine the judicial interpretation to better define the conditions for initiating special representative litigation and improve the coordination between different types of representative litigation [7] - The China Securities Investor Services Center plans to modify relevant business rules to enhance the selection criteria and mechanisms for representative litigation cases [8]

Regulatory Actions - On December 26, ST Fudan (Fudan Zhuhua) announced it received an administrative penalty decision from the Shanghai Regulatory Bureau of the China Securities Regulatory Commission (CSRC) due to false records in its annual reports for 2019, 2020, and 2023, leading to other risk warnings [1] - This penalty will severely impact the company's financing capabilities and market image [1] Financial Misconduct - The CSRC's penalty document revealed specific methods of financial fraud by Fudan Zhuhua, including underreporting operating costs by 50.65 million yuan in 2019, resulting in an inflated total profit of the same amount; underreporting operating costs by 2.59 million yuan in 2020, also inflating total profit; and underreporting asset impairment losses by 27.82 million yuan in 2023, again inflating total profit [2] - The company received a warning and was fined 4 million yuan, with related executives also facing penalties [2] Investor Rights and Legal Actions - Investors participating in lawsuits must pay attention to the statute of limitations and whether they meet the criteria for claims, which include buying shares between April 19, 2014, and March 20, 2024, and selling or holding them at a loss after March 21, 2024, or buying between April 30, 2024, and August 5, 2024, and selling or holding at a loss after August 6, 2024 [3]

Group 1 - The core issue is the continuous financial fraud by *ST Changyao, with the China Securities Regulatory Commission (CSRC) announcing administrative penalties for false financial reporting from 2021 to 2023 [1][4] - The CSRC plans to impose a fine of 10 million yuan on the company and a total of 31 million yuan on 14 responsible individuals, with a total penalty of 41 million yuan [1][4] - The former general manager, Luo Ming, will face a lifetime ban from the securities market [1][4] Group 2 - The company’s stock price has fallen below 1 yuan, triggering a delisting warning [1][4] - Investors are urged to register for compensation, with updated eligibility criteria for claims based on specific purchase and sale dates [1][5] - The company is facing mandatory delisting due to serious violations, with the Shenzhen Stock Exchange initiating delisting procedures [1][5] Group 3 - The financial fraud stemmed from performance pressure following the acquisition of Hubei Changjiang Xing Pharmaceutical Co., Ltd., with commitments made by the original controlling person, Luo Ming, regarding profit targets from 2020 to 2022 [2][5] - Between 2021 and 2023, subsidiaries of Changyao fabricated inventory documents to recognize revenue without actual sales [2][5] Group 4 - The fraudulent financial reports inflated operating income by 215.32 million yuan, 283.74 million yuan, and 233.63 million yuan for the years 2021, 2022, and 2023, respectively [3][6] - The auditing firms for the relevant years will also be investigated and may face penalties, being included as co-defendants in future compensation lawsuits [3][6]

Core Viewpoint - ST HuLuWa is facing severe challenges due to compliance issues and deteriorating performance, leading to regulatory scrutiny and significant financial losses [1][2][4] Group 1: Compliance and Regulatory Issues - ST HuLuWa has received a formal investigation notice from the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws [1] - The company has previously been ordered to rectify financial discrepancies in its 2023 annual report, which included inaccurate revenue and profit disclosures [1] - The company’s internal controls have been deemed severely deficient, resulting in a negative opinion in the 2024 internal control audit report [2] Group 2: Financial Performance - In 2024, ST HuLuWa reported total revenue of 1.414 billion yuan, a year-on-year decline of 21.26%, and a net loss of 274 million yuan, a staggering drop of 2629.23% [2] - For the first half of 2025, the company’s revenue was 508 million yuan, down 42.89% from 889 million yuan in the same period of 2024, with a net profit of only 240,980 yuan, reflecting a 94.14% decline [3] - The core business segment, respiratory medications, saw revenue drop to 299 million yuan, accounting for 58.92% of total revenue, a decrease of 54.22% compared to the previous year [3] Group 3: Market and Operational Challenges - The company is experiencing a vicious cycle where compliance failures lead to a loss of market trust, further exacerbating operational difficulties [4] - Frequent errors in financial reporting and disclosure violations indicate serious deficiencies in internal governance, raising fundamental questions about the company's stability and management effectiveness [4]

图片由AI生成 今日，*ST长药（长江医药控股股份有限公司，股票代码300391.SZ）竞价阶段即封死跌停，股价报1.18元/股，总市值仅剩4.13亿元。 晚间公司同步披露：收到湖北省十堰市中级人民法院裁定，不予受理其重整申请并终结预重整程序，旗下湖北长江星医药等七家子公司实质合并重整程序终 止且被宣告破产。 这场双重崩塌的背后，是12月26日证监会下发的《行政处罚事先告知书》——公司2021年至2023年连续三年财务造假，累计虚增营收7.33亿元、利润1.68亿 元，已触及重大违法强制退市红线，被叠加实施退市风险警示。 距年末仅剩两天，债务豁免、注资等保壳动作已无落地时间窗口，-6.43亿净资产无法转正，财务类退市与重大违法退市双重风险叠加，加之重整之路全面 终结，这家跨界"光伏+医药"的上市公司，终因长期造假与经营溃败走向末路。 | 最高: 1.18 | 今开: 1.18 | 涨停:1.76 | | --- | --- | --- | | 曼低:1.18 | 昨收:1.47 | 跌停:1.18 | | 换手:2.54% | 盘后量:32手 | 量比:0.19 | | 振幅:0.00% | 盘后额:3776 ...